News and Treatment Updates

Highlights In lower-risk MDS subgroup, trisomy 8 and 9 were more frequent in MDS-AID. MDS-AID had fewer tier 1 or 2 mutations than MDS-control or MDS-ALE. ASXL1 mutations were enriched in MDS-ALE within lower-risk MDS. No significant differences in OS or PFS versus MDS-control…

Key Points Chromosome 5q deletion drives progressive chromosome evolution in TP53-mutant preleukemic HSPCs. Aneuploid HSPCs exhibit a shared gene expression signature which confers unique therapeutic vulnerabilities in AML-CK. Clonal acquisition of multiple chromosomal…

On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy…

Abstract Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). While genetic alterations can contribute to resistance, the role of rapid-adaptive non-genetic mechanisms, particularly transcription…

Key Points BCL2 overexpression in T cells is related to a lower risk of GVHD. BCL2 inhibitors should be used with caution after allogeneic hematopoietic stem cell transplantation. Abstract Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality after…

Abstract Background: Myelodysplastic neoplasms (MDS) represent a group of heterogeneous clonal disorders characterized by immune dysregulation in their pathogenesis. Gut microbiota dysbiosis plays a critical role in immune modulation. Methods: We collected the fecal samples of 23…

Key Takeaways Approval targets older/unfit newly diagnosed AML, introducing an all-oral HMA/venetoclax backbone that may reduce infusion burden and expand outpatient feasibility. ASCERTAIN‑V part B delivered DEC‑C days 1–5 q28d with venetoclax ramp-up to 400 mg then 400 mg daily…

ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…

Abstract The Dedicator of Cytokinesis1 (DOCK1) has been implicated in solid tumors; however, its precise role and therapeutic potential in acute myeloid leukemia (AML) remain largely unexplored. Here we investigated the prognostic significance and functional roles of DOCK1 in AML…

Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…